Seres Therapeutics showcased data from its Phase 1b trial of SER-155 at the 2026 ESCMID congress, demonstrating that SER-155 significantly and durably modulates the gut microbiome in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This modulation improves gastrointestinal epithelial barrier integrity, potentially reducing bacterial bloodstream infections (BSIs). The data support SER-155's mechanism to protect the gut barrier and reduce infection risk in immunocompromised patients. Seres also highlighted collaborations using microbiome models for inflammatory bowel disease (IBD) research, indicating broader therapeutic potential. SER-155 is Phase 2 ready and has received Breakthrough Therapy and Fast Track designations, with ongoing trials exploring its use in other immune-related conditions.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Solana (SOL) is currently consolidating above the 0.618 Fibonacci support near $69.86. To confirm a stronger bullish reversal, SOL must break through the $84-$86 resistance zone. A successful breakout could lead to targets of $126 and $180, with anal...
